Merck Expands Production Know-how to Deliver Full End-to-End Solution for Biopharma Industry
News May 03, 2016
Merck, a leading science and technology company has announced that the expansion of single use current good manufacturing process (cGMP) facility with the addition of the Mobius® 2000L single-use bioreactor. With the new upstream suite at its Biodevelopment Center in France, Merck can now offer clients full process line cGMP manufacturing, comprised of Merck's own instrumentation and products.
"Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production," said Udit Batra, CEO, Life Science at Merck. "Our unique offering gives customers the choice to transfer their production at any stage with the confidence that we will ensure the most efficient transition into commercial manufacturing - at either an existing facility or one we help them design."
With this increase in scale and scope, Merck can advance clients' recombinant products from cell line development through to late-stage clinical production. At the point of tech transfer out to a contract manufacturing organization or other facility, clients can also leverage Merck's Provantage® End-to-End Services available worldwide to mitigate the risks traditionally associated with upscaling to commercial production.
Merck's Provantage® End-to-End solution is a comprehensive suite of products and services that include process development, cGMP manufacturing, facility design, manufacturing equipment and consumables, process and equipment training, technology transfer and set-up for commercialization. The offering aims to minimize the risks for customers progressing from early clinical stages to commercial production helping to accelerate time to market and improve productivity and profitability.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018